Anil K. Singhal, Ph.D.

Dr. Anil Singhal has over 3 decades in academic and senior executive roles with large pharmaceutical companies, startups and leading biotech companies.  Dr. Singhal currently serves as the President & CEO of Adicet Bio, a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.  Before joining Adicet Bio, he served as Executive in Residence at Canaan Partners and CSO at OncoResponse Inc.  Dr. Singhal served as Vice President of Early Oncology Development at AbbVie and Head of AbbVie- Redwood City site.  As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases.  Dr. Singhal has held senior roles in the US, Japanese and German biopharma/ biotechnology industry for over 30 years.  Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.

Dr. Singhal holds a PhD from Wakesman Institute of Rutgers University and an Executive MBA from University of Washington.